w6 32 antibody  (Bio X Cell)

Journal: bioRxiv

Article Title: Cytokine-bearing Bacterial Outer Membrane Vesicles with Empowered Efficacy in Intratumoral Immunotherapy

doi: 10.64898/2026.04.02.716109

Figure Lengend Snippet: Representative image of H&E staining MPO immunohistochemistry on FFPE sections of the same tumors described in . CT26 tumors were collected 24 hours after a three intratumoral injections of PBS (50 µL) ( A ) or IL-2-OMVs Δ60 + TNFα-OMVs Δ60 (10 µg in 50 µL PBS) ( B ).( C - D - E ) Flow cytometry analysis of tumors – BALB/c mice were challenged with CT26 and when tumors reached a size of approximately 100 mm 3 mice were treated with one or three doses (two days apart) of the following formulations: PBS (control), 1 μg of OMVs Δ60 , 1 μg of CCL3-OMVs Δ60 , 1 μg of Flt3L-OMVs Δ60 . The day after the treatments, two tumors from each group receiving one dose (Post I) and three tumors from each group receiving three doses (Post III) were surgically removed. Tumor cells (1 x 10 6 ) were incubated with the appropriate fluorescent labelled antibodies and subsequently an alyzed by flow cytometry. Frequencies of regulatory T cells ( C ) γδ T cells ( D ) and LY6C/G + CD11b + myeloid cells ( E ) are calculated within the live, non-aggregated total cell populations. The dotted areas within the bars of panel D indicate the percentage of MHC II-positive γδ T cells. In panel E , each bar is subdivided into three portions of different color intensity. The dark tone represents the fraction of LY6C/G HIGH CD11b MEDIUM cells, the intermediate tone represents the fraction of LY6C/G MEDIUM CD11b HIGH cells and the light tone represents the fraction of myeloid cells excluded by the selected gating parameters. Finally, the dotted areas within each bar represent the fraction of each cell population which is MHC II-positive. The statistical analysis (unpaired, two-tailed Student’s t -test) shown in the right-hand graph refers to the populations of LY6C/G MEDIUM CD11b HIGH cells present in each group (indicated by the lines next to the bars).

Article Snippet: B) 25 μL of the following mixture of fluorescent-labeled antibodies were added to the samples: CD3-APC (BioLegend, San Diego, CA, USA), CD4-BV510 (BioLegend, San Diego, CA, USA), CD8a-PECF594 (BD Bioscience, San Jose, CA, USA), TCRγδ-PE (Miltenyi Biotech, Bergisch Gladbach, Germany), TCRαβ-PEVio770 (Miltenyi Biotech, Bergisch Gladbach, Germany) and MHC II (I-Ek)-VioBright (Miltenyi Biotech, Bergisch Gladbach, Germany).

Techniques: Staining, Immunohistochemistry, Flow Cytometry, Control, Incubation, Two Tailed Test

Journal: Molecular Cancer Therapeutics

Article Title: NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome

doi: 10.1158/1535-7163.MCT-25-0864

Figure Lengend Snippet: NOUS-209 FSMs lost, gained, and kept between paired tumors. A, Timeline plot illustrating the follow-up of patients. Filled dots indicate primary and metachronous colorectal cancer and urothelial cancer. Empty circles denote colorectal cancer for which a tumor sample is not available. Light blue lines indicate the time interval between two tumor occurrences. B, Box plot showing, for each patient, the number of NOUS-209 FSMs lost between the first and second tumor, those kept across both tumors, and those gained in the second tumor. C, Box plot showing, for each patient, the median length of NOUS-209 FSMs lost, kept, and gained. D, Bar plot showing for each patient the number of MHC-I–predicted binders (IC 50 < 500 nmol/L) for lost, kept, and gained FSMs, with annotations for B2M IHC results below for primary (P) and metachronous (M) samples. E, Box plots showing, for each patient, the number of predicted epitopes of NOUS-209 FSM lost, kept, and gained. F, Heatmap showing the FSMs lost for each patient, for whom immune editing is hypothesized. FSMs present in the patient's sample are colored if lost or kept. G, Venn diagram showing the overlap of mutations across the three tumors from patient Pt8. H–J, Line plots for patient Pt8 showing the number of NOUS-209 FSM ( H ), their median length ( I ), and the number of predicted good binders ( J ) across the lost, kept, and gained categories. CRC, colorectal cancer; UC, urothelial cancer.

Article Snippet: MHC class I peptide binding affinity predictions were conducted using the Immune Epitope Database and Analysis Resource MHC class I (MHC-I) prediction tools (RRID: SCR_006604).

Techniques: